Anika Therapeutics(US:ANIK)2026-03-02 23:49Revenue Performance - Revenue for the year ended December 31, 2025 was $112.8 million, a decrease of $7.1 million, or 6%, compared to the prior year[253]. - Revenue from the OEM Channel decreased 17% to $64.4 million, primarily due to a $12.6 million decrease in revenue from J&J MedTech[254]. - Revenue from the Commercial Channel increased 15% to $48.4 million, driven by international sales growth of Cingal and Orthovisc[255]. - Revenue for the year ended December 31, 2024 was $119.9 million, a decrease of $0.9 million, or 1%, compared to the prior year, driven by lower sales activity with OEM channel partners[274]. - Revenue from the OEM Channel decreased by 8% for the year ended December 31, 2024, primarily due to lower volumes and pricing from J&J MedTech, resulting in a total decrease of $4.3 million and $1.6 million respectively[275]. - Revenue from the Commercial Channel increased by 17% for the year ended December 31, 2024, attributed to international sales growth of OA Pain Management products, contributing an increase of $4.3 million[276]. - J&J MedTech accounted for 50% of total revenue for the year ended December 31, 2025, down from 57% in the prior year[283]. - Approximately $27.6 million of the company's revenue was denominated in foreign currencies, primarily the Euro and UK pound sterling, for the year ended December 31, 2025[313]. Profitability and Expenses - Gross profit for 2025 was $63.8 million, with a gross margin of 57%, down from $76.0 million and 63% in 2024[256]. - Adjusted EBITDA for the year ended December 31, 2025 was $5.3 million, a decrease of $10.2 million compared to 2024, primarily due to lower revenues related to J&J MedTech and higher manufacturing costs[268]. - The loss from continuing operations for 2025 was $10.0 million, compared to a loss of $8.8 million in 2024[262]. - The loss from operations for the year ended December 31, 2024 was $5.1 million, compared to income from operations of $0.8 million in the prior year, reflecting a decrease of $5.9 million due to lower gross profit and higher R&D costs[281]. - Adjusted net income from continuing operations in 2025 was $1.6 million, a decrease of $0.8 million compared to 2024, primarily due to lower revenues and higher manufacturing expenses[271]. Research and Development - Research and development expenses for 2025 were $25.8 million, a slight increase of 1% compared to 2024[258]. - Research and development expenses for the year ended December 31, 2024 were $25.5 million, an increase of $3.7 million, or 17%, driven by compliance with regulatory requirements and product development costs[278]. - The company plans to continue investing in research and development for new products, particularly focusing on HA-based technology, funded by cash on hand and future operations[291]. Cash Flow and Financial Position - Cash and cash equivalents totaled $57.5 million as of December 31, 2025, compared to $55.6 million in 2024, while working capital decreased from $90.3 million in 2024 to $80.2 million in 2025[286]. - Cash provided by operating activities increased to $11.2 million in 2025 from $5.4 million in 2024, primarily due to a lower net loss[290]. - Cash used in investing activities decreased to $0.4 million in 2025 from $8.3 million in 2024, mainly due to proceeds from the sales of Arthrosurface and Parcus Medical[292]. - Cash used in financing activities was $10.6 million in 2025, a decrease from $12.7 million in 2024, attributed to reduced stock repurchases[293]. - The company has a credit facility of up to $150 million, with no outstanding borrowings as of December 31, 2025[287]. Strategic Decisions and Divestitures - The company divested Arthrosurface Incorporated in October 2024 and Parcus Medical, LLC in March 2025 to refine its strategic focus[245]. - The company expects to remain dependent on a small number of large customers for a significant portion of its revenues in the near term[284]. Inventory Management - The company writes down inventory when conditions suggest it may exceed anticipated demand or become obsolete, regularly evaluating inventory value based on historical usage rates and market conditions[310]. - Inventory write-downs aim to reduce carrying value to net realizable value, with potential for additional write-downs if actual demand deteriorates or market conditions worsen[311]. Foreign Currency Exposure - Foreign currency fluctuations may adversely affect earnings, with no hedging arrangements in place for transactions in foreign currencies[313]. - The impact of currency exchange rate fluctuations related to international subsidiaries was insignificant in 2025[313]. - The company recognizes foreign currency gains or losses in the period incurred[313].